Thromboembolische Erkrankungen aus kardiologischer Sicht

Thromboembolische Erkrankungen können zu kardiologischen Notfällen mit einer hohen Mortalität führen. Deren Erkennung, akute Behandlung und Sekundärprävention stellen daher einen wesentlichen Behandlungsschwerpunkt in der kardiologischen Praxis dar. Dieser Beitrag zeigt das kardiologische Work-up sowie die medikamentöse und interventionelle Therapie bei thromboembolischen Erkrankungen im venösen und im arteriellen Stromgebiet.

Abstract

Thromboembolic disease is associated with a high mortality. It can be divided into two groups: embolism from a venous and embolism from an arterial side. This article gives an overview on thromboembolic disease (with a focus on pulmonary embolism and ischemic stroke) from a cardiologist’s perspective.

The therapeutic options for acute pulmonary embolism range from anticoagulation to fibrinolysis to interventional recanalization and surgery. The deciding factor for choice of therapy is the risk of early death. Besides clinical parameters, laboratory markers like cardiac troponin and right ventricular function on echocardiography or CTPA (computed tomography pulmonary angiography) are used to determine the early mortality risk. In hemodynamically instable patients, immediate thrombolysis is required, whereas patients with intermediate and low risk can be treated with anticoagulation. Interventional recanalization is currently being studied in patients at risk for development of CTEPH (chronic thromboembolic pulmonary hypertension) or an intermediate risk of early mortality.

In ischemic stroke, early interdisciplinary workup involving a cardiologist is paramount. Post stroke screening should include monitoring for arrythmias (especially atrial fibrillation) and transthoracic echocardiography as well as sonography of extra- and intracranial arteries. If no embolic source can be detected (embolic stroke of undetermined source), transesophageal echo can be helpful to detect intracardiac shunts like patent foramen ovale (PFO) or intracardiac tumors. Post stroke care includes secondary prevention measures like risk factor modification and lipid lowering therapy as well as anticoagulation. In high risk for paradoxical embolization, interventional PFO closure can be performed. Interventional closure of the left atrial appendage (LAA) can be discussed in patients with both high thromboembolic and bleeding risk.

Kernaussagen

• Thromboembolien im venösen System können Lungenarterienembolien hervorrufen oder über einen Rechts-links-Shunt paradox ins arterielle Gefäßsystem embolisieren.

• Thromboembolien im arteriellen System haben multiple Ursachen und können arterielle Verschlüsse in jedem Organsystem verursachen.

• Die Therapie der akuten Lungenarterienembolie richtet sich nach dem frühen Sterbe- und Blutungsrisiko.

• In der Akutphase des Schlaganfalls treten kardiale Komplikationen gehäuft auf. Dieses Stroke-Heart-Syndrom resultiert aus einer neurogenen Dysregulation.

• Bei Verdacht auf einen ischämischen Insult durch eine paradoxe Embolie sollte vor interventionellem PFO-Verschluss ein sorgfältiger Ausschluss von alternativen Schlaganfallursachen erfolgen.

Schlüsselwörter

Lungenembolie - ischämischer Insult - thromboembolische Erkrankungen

Keywords

pulmonary embolism - ischemic stroke - thromboembolic disease

Publication History

Article published online:
07 July 2023

• Literatur

• 1 Douma RA, Gibson NS, Gerdes VE. et al. Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thromb Haemost 2009; 101: 197-200 (PMID: 19132208)
• 2 Konstantinides SV, Meyer G. The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. Eur Heart J 2019; 40: 3453-3455 DOI: 10.1093/eurheartj/ehz405. (PMID: 31504429)
• 3 Kearon C, de Wit K, Parpia S. et al. Diagnosis of pulmonary embolism with d-dimer adjusted to clinical probability. N Engl J Med 2019; 381: 2125-2134
• 4 Doehner W, Mazighi M, Hofmann BM. et al. Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table. Eur J Prev Cardiol 2020; 27: 682-692
• 5 Hart RG, Diener HC, Coutts SB. et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13: 429-438 DOI: 10.1016/S1474-4422(13)70310-7. (PMID: 24646875)
• 6 Tsivgoulis G, Katsanos AH, Kohrmann M. et al. Duration of implantable cardiac monitoring and detection of atrial fibrillation in ischemic stroke patients: a systematic review and meta-analysis. J Stroke 2019; 21: 302-311 DOI: 10.5853/jos.2019.01067. (PMID: 31590474)
• 7 Kleindorfer DO, Towfighi A, Chaturvedi S. et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke 2021; 52: e364-e467
• 8 Katsanos AH, Bhole R, Frogoudaki A. et al. The value of transesophageal echocardiography for embolic strokes of undetermined source. Neurology 2016; 87: 988-995 DOI: 10.1212/WNL.0000000000003063. (PMID: 27488602)
• 9 von Rennenberg R, Siegerink B, Ganeshan R. et al. High-sensitivity cardiac troponin T and severity of cerebral white matter lesions in patients with acute ischemic stroke. J Neurol 2019; 266: 37-45
• 10 Mochmann HC, Scheitz JF, Petzold GC. et al. Coronary angiographic findings in acute ischemic stroke patients with elevated cardiac troponin: the troponin elevation in acute ischemic stroke (TRELAS) study. Circulation 2016; 133: 1264-1271
• 11 Donze J, Le Gal G, Fine MJ. et al. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost 2008; 100: 943-948 DOI: 10.1160/th08-05-0285. (PMID: 18989542)
• 12 Sanchez O, Charles-Nelson A, Ageno W. et al. Reduced-dose intravenous thrombolysis for acute intermediate-high-risk pulmonary embolism: Rationale and design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. Thromb Haemost 2022; 122: 857-866 DOI: 10.1055/a-1653-4699. (PMID: 34560806)
• 13 Pengo V, Denas G, Zoppellaro G. et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132: 1365-1371
• 14 Bajaj NS, Kalra R, Arora P. et al. Catheter-directed treatment for acute pulmonary embolism: Systematic review and single-arm meta-analyses. Int J Cardiol 2016; 225: 128-139 DOI: 10.1016/j.ijcard.2016.09.036. (PMID: 27718446)
• 15 Kucher N, Boekstegers P, Muller OJ. et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129: 479-486 DOI: 10.1161/CIRCULATIONAHA.113.005544. (PMID: 24226805)
• 16 Klok FA, Piazza G, Sharp ASP. et al. Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. Am Heart J 2022; 251: 43-53 DOI: 10.1016/j.ahj.2022.05.011. (PMID: 35588898)
• 17 Zonneveld TP, Richard E, Vergouwen MD. et al. Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev 2018; 7: CD007858 DOI: 10.1002/14651858.CD007858.pub2. (PMID: 30024023)
• 18 Amarenco P, Bogousslavsky J, Callahan 3rd A. et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559 DOI: 10.1056/NEJMoa061894. (PMID: 16899775)
• 19 Lee PH, Song JK, Kim JS. et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol 2018; 71: 2335-2342 DOI: 10.1016/j.jacc.2018.02.046. (PMID: 29544871)
• 20 Kent DM, Ruthazer R, Weimar C. et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013; 81: 619-625 DOI: 10.1212/WNL.0b013e3182a08d59. (PMID: 23864310)
• 21 Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996; 61: 755-759 DOI: 10.1016/0003-4975(95)00887-X. (PMID: 8572814)
• 22 Reddy VY, Doshi SK, Kar S. et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 2017; 70: 2964-2975
• 23 Osmancik P, Reddy VY. Reply: Primary Composite Outcome in PRAGUE-17: An Unintended Butterfly Effect. J Am Coll Cardiol 2022; 79 (25) e499
• 24 Tamin SS, Maleszewski JJ, Scott CG. et al. Prognostic and bioepidemiologic implications of papillary fibroelastomas. J Am Coll Cardiol 2015; 65: 2420-2429 DOI: 10.1016/j.jacc.2015.03.569. (PMID: 26046736)
• 25 Stimpfle F, Muller K, Geisler T. et al. Thromboembolic risk reduction via transseptal thrombus aspiration in a patient with spontaneous left atrial thrombus and stroke. JACC Cardiovasc Interv 2017; 10: e57-e59